| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_65d3cdbfecf69ab04bcfbb50b072bf64 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6827
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2009-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c2b619b506155e614a6a4126cf81956
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c698e09fde190d38e50935d41040ed24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f844839473414046fc27884617435460
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d65b446b59b3d7363fbe581a2b16d2c9 |
| publicationDate |
2012-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2514841-A1 |
| titleOfInvention |
Methods and compositions for the assessment of drug response |
| abstract |
The present invention relates to a method comprising: na) analyzing a sample from a subject with a SNP detection assay to determine that said subject is homozygous for the -806C/T polymorphism in the CYP2C19 gene (CYP2C19*17), thereby generating a homozygous CYP2C19*17 genetic analysis result; and- nb) processing said homozygous CYP2C19*17 genetic analysis result to generate an outcome that indicates that said subject should receive decreased loading and/or maintenance dosages of a thienopyridine anti-platelet agent compared to CYP2C19 wild-type dosage levels. |
| priorityDate |
2008-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |